🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in the Netherlands / NCT06074614
Recruiting Observational

Neural Control of Breathing in Parkinson's Disease

NCT06074614 · tracked via the Priya Life Science Netherlands tracker
Phase
Observational
Started
2023-10-30
Last updated
2024-12-20

Condition(s) studied

Parkinson Disease

Investigational drug(s) / intervention(s)

Hypercapnic ventilatory responseRespiratory related evoked potentialTranscranial magnetic stimulation

Hypercapnic ventilatory response: Control of breathing is predominantly regulated by feedback of the central chemoreceptors. All chemoreceptors are sensitive to changes in partial pressure of carbon dioxide and via acid-base reactions to hydrogen concentration. The hypercapnic ventilatory response test shows the relationship between end-tidal PCO2 and the resulting minute ventilation.

Respiratory related evoked potential: The RREP is a measure of cerebral cortical activity elicited by short inspiratory occlusion or breathing against inspiratory resistive loads and quantifies the initial arrival and further processing of sensory afferent respiratory information in the cortex.

Transcranial magnetic stimulation: Transcranial magnetic stimulation of the diaphragm is an established tool for investigating the cortical excitability related to breathing. TMS will be delivered over the vertex using a magnetic stimulator and a 110mm double cone coil.

Study summary

Breathing is a complex process, which can be controlled through voluntary command or neural control. Parkinson's disease (PD) is a progressive neurological disorder. Many individuals with PD experience respiratory problems, such as coughing difficulties or shortness of breath. Changes in neural control of breathing could be part of the reason of these respiratory problems. This study will measure whether neural control of breathing is impaired in individuals with PD compared to healthy individuals.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy subjects: competent adult (\>18 years) volunteers * Patients: adult (\<18 years) patients with Parkinson's disease, clinically confirmed by a movement disorder specialised neurologist with Hoehn and Yahr staging 1 to 3 * Willingness and ability to understand nature and content of the study * Ability to participate and comply with study requirements Exclusion Criteria: * Healthy subjects: previous or ongoing diseases of the central nervous system * Patients: previous or ongoing diseases of the central nervous system, other than Parkinson's disease * History of or current psychiatric treatment * History of or current brain surgery or epilepsy, unclusing deep brain stimulation * Neuromuscular disorders * Pre-existing pulmonary disease, such as chronic obstructive pulmonary disease, asthma or pulmonary fibrosis * TMS incompatibility (metal parts in head or neck, skin allergies) * Implanted cardiac pacemaker or defibrillator, neurostimulator, cochlear implant or medical infusion device * Large or ferromagnetic metal parts in the head (exept for a dental wire) * Pregnancy * Smoking

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Radboudumc Nijmegen Gelderland Recruiting

More Radboud University Medical Center trials in the Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06074614 on ClinicalTrials.gov ↗ ← All trials in the Netherlands